Recent News

• 10.30.2025 - INmune Bio Inc. Announces Third Quarter 2025 Results and Provides Business Update
• 10.23.2025 - INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025
• 10.14.2025 - INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025
• 09.29.2025 - INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal
• 09.15.2025 - INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult

Recent Filings

• 10.30.2025 - 10-Q Quarterly report [Sections 13 or 15(d)]
• 10.30.2025 - EX-99.1 EX-99.1
• 10.30.2025 - 8-K Current report
• 10.28.2025 - 8-K Current report
• 10.28.2025 - EX-99.1 EX-99.1
• 10.14.2025 - 8-K Current report
• 10.14.2025 - EX-99.1 EX-99.1
• 10.14.2025 - DEF 14A Other definitive proxy statements
• 10.03.2025 - PRE 14A Other preliminary proxy statements
• 09.30.2025 - EX-99.1 EX-99.1